# A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

> **NCT04599855** · PHASE4 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 477 (actual)

## Conditions studied

- Depressive Disorder, Treatment-Resistant

## Interventions

- **DRUG:** Esketamine 56 mg
- **DRUG:** Esketamine 84 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04599855
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599855, "A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04599855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*